✦ LIBER ✦

Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck

✍ Scribed by Stephen D. Williams; Robert Birch; Enrique Velez-Garcia; Richard Gams

Publisher: Springer US
Year: 1985
Tongue: English
Weight: 170 KB
Volume: 3
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00179438

No coin nor oath required. For personal study only.

✦ Synopsis

A phase II study of mitoxantrone in squamous cell carcinoma of head and neck origin was conducted. Fiftythree evaluable patients were treated with this agent at a dosage of 5 mg/M2/week. The majority of patients were of high performance status. Twenty-seven patients had received previous chemotherapy plus surgery and/or radiotherapy. Twenty-six had not been treated with chemotherapy previously although thirteen of these patients had prior radiotherapy and surgery, eight radiotherapy only, one surgery only, and four no previous treatment. There was only one objective response. Toxicity was relatively mild, although 45% of the patients at some time experienced at least moderate leukopenia. Further studies of this agent in this disease are not warranted.

📜 SIMILAR VOLUMES

A phase II study of mitoxantrone in adva

A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck

✍ H. Wheeler; R. L. Woods; J. Page; J. Levi 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 186 KB

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two

Phase II study of amonafide in the treat

Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck

✍ Fred Rosen; Everett E. Vokes; Thomas Lad; Merrill Kies; James Wade; Lary J. Kilt 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 299 KB

Hyperfractionated radiotherapy in advanc

Hyperfractionated radiotherapy in advanced squamous cell carcinoma of the head and neck

✍ Tan Dat Nguyen; Xavier Panis; Michel Legros; Dominique Froissart 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 329 KB

A phase II study of adriamycin in previo

A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck

✍ Melody A. Cobleigh; James H. Hill; Patricia A. Gallagher; Lawrence J. Kukla; Tho 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 2 views

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m\* at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 eval

Multicenter phase II trial of brequinar

Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck

✍ Susan Urba; James Doroshow; Christine Cripps; Francisco Robert; Enrique Velez-Ga 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 260 KB

Combination chemotherapy for advanced sq

Combination chemotherapy for advanced squamous cell carcinoma of the head and neck

✍ Coker, Donald D. ;Elias, E. George ;Chretien, Paul B. ;Gray, William C. ;Coleman 📂 Article 📅 1981 🏛 Wiley (John Wiley & Sons) ⚖ 639 KB

## Abstract Fifty‐one patients (32 previously untreated, 19 previously treated) with advanced squamous cell carcinoma of the head and neck received a single course of combination chemotherapy consisting of high dose __cis__‐platinum (DDP), bleomycin (Bleo), ± high dose methotrexate (MTX). Thirty‐th